Safety , Pharmacokinetics and efficacy of QAV680 in asthma patients
Phase 2
Completed
- Registration Number
- CTRI/2009/091/000282
- Lead Sponsor
- ovartis Healthcare Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
Mild to moderate asthma for at least 6 months.
Exclusion Criteria
Past or recent history of significant medical illness and/or lab abnormalities including but not limited to ECG abnomalities, abnormal LFT, HIV, Hep B/C, allergic disorders, pancreatic disease, serious underlying respiratory diseases, life threatning asthma, renal disease etc
Surgical and/or medical conditions which significantly effect ADME of the drug.
Prior use of asthma medications (except SABA's) prior to 2 weeks of dosing
Other protocol-defined inclusion/exclusion criteria may apply
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method